The final expert opinion on rotavirus vaccination in infancy aims to provide EU/EEA Member States with information to support the decision-making process on the possible introduction of rotavirus vaccination in infancy.
On the occasion of the tenth anniversary of European Immunization Week, ECDC is releasing a new complement of data, tools, blogs and updates to support public health authorities in their work against vaccine preventable diseases.
This report describes the occurrence of invasive bacterial diseases (IBD) in Europe during 2012, based on data collected through The European Surveillance System (TESSy).
This report presents the epidemiological situation for vaccine-preventable diseases – invasive bacterial diseases (invasive Haemophilus influenzae, meningococcal and pneumococcal disease) as of 2012 and describes the statistical and epidemiological methods used.
This report on EQA performance shows that European Reference Laboratories for Meningococci differ in their capacities and the level of characterisation of the distributed N. meningitidis material, but that there have been improvements since the first ECDC IBD-labnet distribution.
In Europe, routine rotavirus vaccination of infants at the national level has been introduced with one or two vaccine brands in Finland, Austria, Luxembourg and Belgium within well-baby clinics or administered by general practitioners and paediatricians. When introducing a new vaccine, it is crucial to conduct studies evaluating the vaccination’s impact and effectiveness in order to decide on recommendations for its future use.
When introducing a new vaccine, it is crucial to conduct studies evaluating the vaccination’s impact and effectiveness in order to decide on recommendations for its future use. To this end, ECDC has produced three generic protocols.